FMD alone would not be sufficient for restoring endocrine sensitivity in all breast cancers, as tumors with constitutive activation of PI3K/Akt/mTOR signaling are likely to be resistant to fasting approaches [179]. Here, AKT1 is linked to breast carcinoma.